Desmopressin: profile and news
Federal Court Affirms Barr Summary Judgment in DDAVP(R) Patent ... Feb 15, 2006
...judgment in favor of its wholly owned subsidiary, Barr Laboratories, Inc., in the Company's challenge to the patent for DDAVP(R) (Desmopressin Acetate) Tablets ... - Black Enterprise,
Sanofi expects Acomplia launch in 06; profits up Feb 24, 2006
...to four products, the antihistamine Allegra (fexofenadine), diabetes drug Amaryl (glimepiride), Arava (leflunomide) for arthritis and DDAVP (desmopressin). ... - Pharma Times (subscription),
ZLB Behring Announces Availability of Humate-P(R) with Smaller ... Feb 15, 2006
...spontaneous and trauma-induced bleeding episodes in severe von Willebrand Disease (VWD), and in mild or moderate VWD where the use of desmopressin is known or ... - PR Newswire (press release),
Barr Reports Second Quarter Fiscal 2006 GAAP Earnings of $0.88 Per ... Feb 7, 2006
The $24 million increase is primarily related to strong sales of the Company's Desmopressin product that was launched in July 2005 and sales of its Didanosine ... - MSN Money
Barr Should Get Earnings Boost From Key Drugs Feb 6, 2006
...from the lack of additional generic market competition and an extended period of market exclusivity for its generic version of DDAVP (desmopressin acetate). ... - TheStreet.com
Barr reports strong quarterly earnings Feb 8, 2006
The rise in overall generic sales was largely attributable to Barr's introductions of its versions of desmopressin, used to treat bed wetting and frequent ... - The Journal News.com,
Barr prevails in DDAVP patent appeal Feb 15, 2006
Barr makes generic desmopressin acetate tablets in 0.1 mg and 0.2 mg strengths. Ferring manufactures the brand drug for Aventis. ... - United Press International
Head-to-Head Study Shows EUFLEXXA(TM) Has Greater Tolerability ... Feb 13, 2006
...include ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome and generic desmopressin acetate in ... - PR Newswire (press release),
Teva Announces Approval of Desmopressin Acetate Tablets Jan 29, 2006
...(Nasdaq: TEVA) announced today that the US Food and Drug Administration has granted final approval for the Company's ANDA for Desmopressin Acetate Tablets, 0.1 ... - International News Service,
FDA approval for Teva's desmopressin acetate tablets Jan 29, 2006
...the US Food and Drug Administration (FDA) has granted final approval for the company's abbreviated new drug application (ANDA) for desmopressin acetate tablets ... - Globes,
Desmopressin improves nighttime urination in men Jan 17, 2006
NEW YORK (Reuters Health) - Desmopressin safely relieves frequent nighttime urination or "nocturia" in elderly men who've tried other medications to control ... - Reuters.uk,
Ranbaxy to sell Swiss Ferring's Desmopressin in India Jan 10, 2006
...said on Tuesday it struck a marketing deal with Swiss biopharma company Ferring International to sell hormone tablet Desmopressin in India. ... - Reuters India,
Barr reports strong quarterly earnings Feb 8, 2006
The rise in overall generic sales was largely attributable to Barr's introductions of its versions of desmopressin, used to treat bed wetting and frequent ... - The Journal News.com,
Barr Reports Second Quarter Fiscal 2006 GAAP Earnings of $0.88 Per ... Feb 7, 2006
The $24 million increase is primarily related to strong sales of the Company's Desmopressin product that was launched in July 2005 and sales of its Didanosine ... - PR Newswire (press release),
Drug improves nighttime urination in men Jan 17, 2006
NEW YORK, JANUARY 18 : Desmopressin safely relieves frequent nighttime urination or "nocturia" in elderly men who've tried other medications to control their ... - Financial Express,
Barr Should Get Earnings Boost From Key Drugs Feb 6, 2006
...from the lack of additional generic market competition and an extended period of market exclusivity for its generic version of DDAVP (desmopressin acetate). ... - TheStreet.com
Ranbaxy signs mktg deal with Ferring Intl Jan 10, 2006
Ranbaxy Laboratories has signed a co-marketing agreement with Switzerland-based Ferring International for marketing Ferring's Desmopressin. ... - Business Standard,
Ranbaxy gets into mktg agreement with Swiss Company Jan 10, 2006
...maker Ranbaxy Laboratories today signed a co-marketing agreement with Switzerland-based Ferring International for marketing Ferring’s Desmopressin as part of ... - NewKerala.com,
Ranbaxy to co-market Ferrings` urology drug Jan 10, 2006
...into a co-marketing agreement with Switzerland-based Ferring International, a speciality biopharmaceutical company, for the latter’s product Desmopressin. ... - Business Standard,
RANBAXY: Ranbaxy To Co-Market Ferring's Urology Drug In India ... Jan 11, 2006
...into a co-marketing agreement with Ferring International of Switzerland, a speciality biopharmaceutical company, for its product Desmopressin, a structural ... - Webbolt Business News (subscription),
Ranbaxy ties up with Swiss Co to sell its drug in India Jan 10, 2006
Mumbai: Ranbaxy has signed a co-marketing agreement with Swiss company Ferring International for selling its drug Desmopressin in the country under the brand ... - NewKerala.com,
Ranbaxy enters into co-marketing agreement with Swizz co Jan 10, 2006
Tuesday entered into a co-marketing agreement with Switzerland-based Ferring International, a specialty biopharmaceutical company, for its product Desmopressin ... - Hindustan Times,
Ranbaxy enters into agreement with Ferring International ... Jan 10, 2006
Laboratories (Q, N,C,F)* Ltd has entered into a co-marketing agreement with Ferring International of Switzerland, for its product Desmopressin, a structural ... - Myiris.com,
Ranbaxy signs co-marketing pact with Ferring 1/10/2006 1:49:45 PM ... Jan 10, 2006
...that it has entered into a co-marketing agreement with Ferring International of Switzerland, a specialty biopharmaceutical company, for its product Desmopressin ... - India Infoline.com,
Ranbaxy in co-marketing agreement with Ferring of Switzerland Jan 10, 2006
...entered into a co-marketing agreement with Ferring International of Switzerland, a specialty biopharmaceutical firm, for its product Desmopressin; a structural ... - domain-B,
Sensex slides 138 points Jan 10, 2006
...gained 4 per cent after the company said it had struck a marketing deal with Swiss company Ferring International to sell hormone tablet Desmopressin in India. ... - Business Standard,
Indian shares fall ahead of Reliance Jan 10, 2006
...to 393.75 rupees after it said it had struck a marketing deal with Swiss biopharma company Ferring International to sell hormone tablet Desmopressin in India. ... - Reuters India,
Wrap up: Sensex slumps 138 points Jan 10, 2006
...on the news that the company has entered into a co-marketing agreement with Ferring International of Switzerland, for its product Desmopressin, a structural ... - Myiris.com,
Ranbaxy Year 2005 Global Sales at USD 1178 Mn Jan 18, 2006
Recently the Company entered into a co-marketing agreement with Ferring International of Switzerland, for its product Desmopressin, The in-licensing agreement ... - PharmaLive.com (press release),
FAMILY DOCTOR: New drugs can help reduce so many nighttime trips ... Dec 7, 2005
...in increased fluid loss. An ADH-like drug called desmopressin has been used successfully to treat nocturia. About three-fourths ... - Canton Repository (subscription),
Ferring Pharmaceuticals Announces Launch of EUFLEXXA for ... Nov 14, 2005
...include ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome and generic desmopressin acetate in ... - PharmaLive.com (press release),
Leading Urology Experts Call For Better Recognition And Treatment ... Sep 10, 2005
...at the 35th Annual Meeting of the International Continence Society (ICS) in Montreal, Canada, confirmed the benefits of MINIRIN® (desmopressin) in the ... - I-Newswire.com (press release)
No-Transfusion Liver Graft in Surgical Tour de Force Sep 26, 2005
...and the coagulopathy was more difficult to control in the absence of blood products in the face of kidney failure despite the use of desmopressin acetate and ... - MedPage Today,
Positive approach to dealing with bedwetting Sep 12, 2005
...help. If all these don’t work, medication can be an alternative. "Desmopressin acetate is the most common medication in use. It ... - New Straits Times,
Barr Reports GAAP Earnings of $2.03 Per Share for Fiscal 2005 and ... 08 Sep 2005
...the fourth quarter of fiscal 2005 were lower than expected due primarily to the timing of FDA approval of the Company's DDAVP(R) (Desmopressin Acetate) Tablets ... - PR Newswire (press release),
Barr Reports GAAP Earnings of $2.03 Per Share for Fiscal 2005 and ... 08 Sep 2005
...the fourth quarter of fiscal 2005 were lower than expected due primarily to the timing of FDA approval of the Company's DDAVP® (Desmopressin Acetate) Tablets ... - Yahoo! News (press release)
Leading Urology Experts Call For Better Recognition And Treatment ... Sep 4, 2005
...at the 35th Annual Meeting of the International Continence Society (ICS) in Montreal, Canada, confirmed the benefits of MINIRIN® (desmopressin) in the ... - Medical News Today (press release),
Major cause of sleep loss to be discussed at International ... Aug 29, 2005
...and women, its causes, approaches to treatment, patient characteristics (long-term studies), effect on quality of life and anti-diuretic therapy (desmopressin ... - Canada NewsWire (press release),
Changes to drug ads may be on the horizon Aug 14, 2005
...needs to rule them out. You may want to ask your doctor whether DDAVP (desmopressin) would be helpful. This hormone is prescribed ... - Houston Chronicle,
First-Time Generic Approvals: Rocephin, Sinemet, DDAVP Jul 8, 2005
...carbidopa/levodopa 10-mg/100-mg, 25-mg/100-mg, and 25-mg/250-mg tablets for the treatment of Parkinson's disease and parkinsonism; and desmopressin acetate 0.1 ... - Medscape (subscription)
Growth lifts B&L revenue forecast Jul 28, 2005
Sales of prescription eye drop brands Lotemax and Alrex were up in the Americas, but were offset by a decline in sales of desmopressin, a generic nasal spray ... - Rochester Democrat and Chronicle
NJ business briefs Jul 6, 2005
Barr will have six months of exclusive sales for the generic version, also known as desmopressin acetate, which treats a disease known as "water diabetes" that ... - NorthJersey.com
Other information
Indication
For the management of primary nocturnal enuresis and indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary
Pharmacology
Desmopressin is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. Desmopressin is indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region and is also indicated for the management of primary nocturnal enuresis.
Mechanism Of Action
Desmopressin emulates the actions of the natural pituitary hormone 8-arginine vasopressin (ADH).
Drug Category
Renal Agents; Hemostatics (20:12.16); Pituitary (68:28.00); ATC:H01BA02
Brand Names/Synonyms
DESMOPRESSIN; Desmopresina [INN-Spanish]; Desmopressine [INN-French]; Desmopressinum [INN-Latin]; 1-Deamino-8-D-arginine vasopressin; 1-Desamino-8-D-arginine vasopressin; 1-Desamino-8-d-arginine-vasopressin; Desamino-8-D-arginine vasopressin, l-; Concentraid; DDAVP; Stimate
Dosage Forms
TABLET
Absorption
Not Available
Interactions
Interactions for Desmopressin:
Although the pressor activity of Desmopressin is very low compared to its antidiuretic activity, large doses of Desmopressin Tablets should be used with other pressor agents only with careful patient monitoring.
Chemical IUPAC Name
1-[[13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-4-yl]carbonyl]-N-[1-(carbamoylmethylcarbamoyl)-4-guanidino-butyl]-pyrrolidine-2-carboxamide
Chemical Formula
C46H64N14O12S2
Half Life
1.5-2.5 hours
Drug Type
Approved Drug
# Accession No
BIOD00112
CAS Registry Number
16679-58-6